Sientra Inc (NASDAQ:SIEN)’s share price reached a new 52-week low on Wednesday . The stock traded as low as $6.41 and last traded at $6.49, with a volume of 25474 shares trading hands. The stock had previously closed at $6.70.
SIEN has been the subject of several research analyst reports. Leerink Swann dropped their price objective on Sientra from $22.00 to $18.00 in a research note on Wednesday, March 13th. ValuEngine downgraded Sientra from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 24th. Craig Hallum set a $23.00 price objective on Sientra and gave the company a “buy” rating in a research note on Tuesday, March 26th. Stifel Nicolaus dropped their price objective on Sientra from $19.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, March 13th. Finally, Dougherty & Co dropped their price objective on Sientra from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Wednesday, March 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $21.00.
The company has a market cap of $189.61 million, a price-to-earnings ratio of -2.18 and a beta of -0.10. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.52 and a quick ratio of 1.16.
Sientra (NASDAQ:SIEN) last released its quarterly earnings data on Wednesday, May 8th. The medical instruments supplier reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.15). The firm had revenue of $17.55 million during the quarter, compared to analysts’ expectations of $17.00 million. Sientra had a negative net margin of 126.32% and a negative return on equity of 119.59%. As a group, analysts predict that Sientra Inc will post -2.95 EPS for the current year.
Large investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Sientra during the 4th quarter valued at $29,000. BNP Paribas Arbitrage SA grew its holdings in Sientra by 97,300.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 4,870 shares of the medical instruments supplier’s stock valued at $42,000 after buying an additional 4,865 shares during the last quarter. Great West Life Assurance Co. Can acquired a new stake in Sientra during the 4th quarter valued at $64,000. Metropolitan Life Insurance Co. NY boosted its holdings in shares of Sientra by 356.6% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,191 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 6,397 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Sientra during the fourth quarter worth $135,000. Hedge funds and other institutional investors own 86.18% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Sientra (SIEN) Sets New 52-Week Low at $6.41” was originally reported by Macon Daily and is owned by of Macon Daily. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://macondaily.com/2019/05/17/sientra-sien-sets-new-52-week-low-at-6-41.html.
About Sientra (NASDAQ:SIEN)
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Further Reading: Certificate of Deposit (CD)
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.